Literature DB >> 34633497

Inter-reader agreement of abbreviated magnetic resonance imaging for hepatocellular carcinoma detection: a systematic review and meta-analysis.

Dong Hwan Kim1, Sang Hyun Choi2, Ji Sung Lee3, Joon-Il Choi1.   

Abstract

PURPOSE: To determine the inter-reader agreement of abbreviated magnetic resonance imaging (AMRI) for the detection of hepatocellular carcinoma (HCC) and explore the causes of heterogeneity between the reported results.
METHODS: Original studies reporting the inter-reader agreement of AMRI for detecting HCC were identified in MEDLINE, EMBASE, and Cochrane databases. The pooled kappa coefficient (κ) was calculated using the DerSimonian-Laird random-effects model. Subgroup analyses were performed according to the AMRI protocol (non-contrast [NC]-AMRI, dynamic contrast-enhanced [DCE]-AMRI, and hepatobiliary phase [HBP]-AMRI). Meta-regression analyses were performed to further explore study heterogeneity.
RESULTS: In the eight included studies (1182 patients), the overall pooled κ was 0.76 (95% confidence interval [CI], 0.70-0.82; I2 = 74.4%). The κ of NC-AMRI, DCE-AMRI, and HBP-AMRI were 0.72 (95% CI, 0.62-0.82), 0.80 (95% CI, 0.78-0.82), and 0.98 (95% CI, 0.95-1.00), respectively. In the NC-AMRI, the pooled κ of NC-AMRI using only diffusion-weighted imaging (DWI) was 0.64, which was lower than the values using two or more imaging sequences (κ = 0.74-0.77). In subgroup analysis, no study heterogeneity was noted in studies using DCE-AMRI (I2 = 0%), whereas high heterogeneity was noted with NC-AMRI (I2 = 80.5%). Especially, NC-AMRI including more than two imaging sequences showed high residual heterogeneity (I2 = 87.6%). Meta-regression analysis found that difference in reader experience was significantly associated with study heterogeneity (p = .02).
CONCLUSION: AMRI for detecting HCC showed substantial inter-reader agreement across all examined protocols. NC-AMRI, notably NC-AMRI using only DWI, had relatively low inter-reader agreement. Therefore, DCE-AMRI or HBP-AMRI may be more reliable than NC-AMRI using only DWI.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Early detection of cancer; Hepatocellular carcinoma; Magnetic resonance imaging; Meta-analysis; Reproducibility of results

Mesh:

Substances:

Year:  2021        PMID: 34633497     DOI: 10.1007/s00261-021-03297-0

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  27 in total

Review 1.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

2.  Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis.

Authors:  Kristina Tzartzeva; Joseph Obi; Nicole E Rich; Neehar D Parikh; Jorge A Marrero; Adam Yopp; Akbar K Waljee; Amit G Singal
Journal:  Gastroenterology       Date:  2018-02-06       Impact factor: 22.682

3.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach
Journal:  Hepatology       Date:  2018-08       Impact factor: 17.425

Review 4.  Abbreviated MRI for Hepatocellular Carcinoma Screening and Surveillance.

Authors:  Julie Y An; Miguel A Peña; Guilherme M Cunha; Michael T Booker; Bachir Taouli; Takeshi Yokoo; Claude B Sirlin; Kathryn J Fowler
Journal:  Radiographics       Date:  2020 Nov-Dec       Impact factor: 5.333

5.  Randomized controlled trial of screening for hepatocellular carcinoma.

Authors:  Bo-Heng Zhang; Bing-Hui Yang; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

6.  Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis.

Authors:  Pankaj Gupta; Raghuraman Soundararajan; Ankur Patel; Praveen Kumar-M; Vishal Sharma; Naveen Kalra
Journal:  J Hepatol       Date:  2021-02-03       Impact factor: 25.083

7.  HCC screening: assessment of an abbreviated non-contrast MRI protocol.

Authors:  Michael Vinchill Chan; Stephen J McDonald; Yang-Yi Ong; Katerina Mastrocostas; Edwin Ho; Ya Ruth Huo; Cositha Santhakumar; Alice Unah Lee; Jessica Yang
Journal:  Eur Radiol Exp       Date:  2019-12-18

8.  MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma.

Authors:  So Yeon Kim; Jihyun An; Young-Suk Lim; Seungbong Han; Ji-Young Lee; Jae Ho Byun; Hyung Jin Won; So Jung Lee; Han Chu Lee; Yung Sang Lee
Journal:  JAMA Oncol       Date:  2017-04-01       Impact factor: 31.777

9.  Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis.

Authors:  Amit G Singal; Anjana Pillai; Jasmin Tiro
Journal:  PLoS Med       Date:  2014-04-01       Impact factor: 11.069

10.  The Diagnostic Performance of Liver MRI without Intravenous Contrast for Detecting Hepatocellular Carcinoma: A Case-Controlled Feasibility Study.

Authors:  Seunghee Han; Joon-Il Choi; Michael Yong Park; Moon Hyung Choi; Sung Eun Rha; Young Joon Lee
Journal:  Korean J Radiol       Date:  2018-06-14       Impact factor: 3.500

View more
  1 in total

1.  Potential of a Non-Contrast-Enhanced Abbreviated MRI Screening Protocol (NC-AMRI) in High-Risk Patients under Surveillance for HCC.

Authors:  François Willemssen; Quido de Lussanet de la Sablonière; Daniel Bos; Jan IJzermans; Robert De Man; Roy Dwarkasing
Journal:  Cancers (Basel)       Date:  2022-08-17       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.